Table Describing Mortality in Patients who Received Appropriate Treatment for CNS Infection Within 12 Hours After Admission, Amphotericin B–Based Treatment for Cryptococcal Meningitis Within 12 Hours After Admission, and Appropriate Tuberculous Meningitis Treatment Within 24 Hours; Logistic Regressions Analysis Adjusting for Age, Sex, Glasgow Coma Score, and Composite NEWS
| Time From Admission to Therapy . | Mortality, % (No.) . | Crude Odds Ratio for Mortality (95% CI, P Value) . | Adjusted Odds Ratio for Mortality (95% CI, P Value) . |
|---|---|---|---|
| Appropriate therapy for all CNS infection | |||
| Under 12 h | 27.5 (11/40) | - | - |
| After 12 h | 35.8 (45/123) | 1.52 (0.69–3.35, .29) | 1.66 (0.66–4.18, .28) |
| Antibiotics in confirmed bacterial meningitis or probable bacterial meningitis with neutrophilic pleocytosis and no confirmed CNS infection | |||
| Under 12 h | 30.4 (7/23) | … | … |
| Over 12 h | 40.0 (2/5) | 1.52 (0.20–11.72, .68) | 2.22 (0.17–29.98, .55) |
| Amphotericin B–based cryptococcal meningitis treatment | |||
| Under 12 h | 18.2 (2/11) | - | - |
| Over 12 h | 32.4 (24/74) | 2.16 (0.43–10.98, .34) | 1.41 (0.24–8.31, .71) |
| Antituberculous treatment in patients with possible, probable, or definite tuberculous meningitis | |||
| Under 24 h | 23.5 (4/17) | - | - |
| Over 24 h | 48.4 (15/31) | 3.05 (0.77–12.10, .10) | 6.89 (1.01–46.99, .05) |
| Time From Admission to Therapy . | Mortality, % (No.) . | Crude Odds Ratio for Mortality (95% CI, P Value) . | Adjusted Odds Ratio for Mortality (95% CI, P Value) . |
|---|---|---|---|
| Appropriate therapy for all CNS infection | |||
| Under 12 h | 27.5 (11/40) | - | - |
| After 12 h | 35.8 (45/123) | 1.52 (0.69–3.35, .29) | 1.66 (0.66–4.18, .28) |
| Antibiotics in confirmed bacterial meningitis or probable bacterial meningitis with neutrophilic pleocytosis and no confirmed CNS infection | |||
| Under 12 h | 30.4 (7/23) | … | … |
| Over 12 h | 40.0 (2/5) | 1.52 (0.20–11.72, .68) | 2.22 (0.17–29.98, .55) |
| Amphotericin B–based cryptococcal meningitis treatment | |||
| Under 12 h | 18.2 (2/11) | - | - |
| Over 12 h | 32.4 (24/74) | 2.16 (0.43–10.98, .34) | 1.41 (0.24–8.31, .71) |
| Antituberculous treatment in patients with possible, probable, or definite tuberculous meningitis | |||
| Under 24 h | 23.5 (4/17) | - | - |
| Over 24 h | 48.4 (15/31) | 3.05 (0.77–12.10, .10) | 6.89 (1.01–46.99, .05) |
Abbreviation: CNS, central nervous system.
Table Describing Mortality in Patients who Received Appropriate Treatment for CNS Infection Within 12 Hours After Admission, Amphotericin B–Based Treatment for Cryptococcal Meningitis Within 12 Hours After Admission, and Appropriate Tuberculous Meningitis Treatment Within 24 Hours; Logistic Regressions Analysis Adjusting for Age, Sex, Glasgow Coma Score, and Composite NEWS
| Time From Admission to Therapy . | Mortality, % (No.) . | Crude Odds Ratio for Mortality (95% CI, P Value) . | Adjusted Odds Ratio for Mortality (95% CI, P Value) . |
|---|---|---|---|
| Appropriate therapy for all CNS infection | |||
| Under 12 h | 27.5 (11/40) | - | - |
| After 12 h | 35.8 (45/123) | 1.52 (0.69–3.35, .29) | 1.66 (0.66–4.18, .28) |
| Antibiotics in confirmed bacterial meningitis or probable bacterial meningitis with neutrophilic pleocytosis and no confirmed CNS infection | |||
| Under 12 h | 30.4 (7/23) | … | … |
| Over 12 h | 40.0 (2/5) | 1.52 (0.20–11.72, .68) | 2.22 (0.17–29.98, .55) |
| Amphotericin B–based cryptococcal meningitis treatment | |||
| Under 12 h | 18.2 (2/11) | - | - |
| Over 12 h | 32.4 (24/74) | 2.16 (0.43–10.98, .34) | 1.41 (0.24–8.31, .71) |
| Antituberculous treatment in patients with possible, probable, or definite tuberculous meningitis | |||
| Under 24 h | 23.5 (4/17) | - | - |
| Over 24 h | 48.4 (15/31) | 3.05 (0.77–12.10, .10) | 6.89 (1.01–46.99, .05) |
| Time From Admission to Therapy . | Mortality, % (No.) . | Crude Odds Ratio for Mortality (95% CI, P Value) . | Adjusted Odds Ratio for Mortality (95% CI, P Value) . |
|---|---|---|---|
| Appropriate therapy for all CNS infection | |||
| Under 12 h | 27.5 (11/40) | - | - |
| After 12 h | 35.8 (45/123) | 1.52 (0.69–3.35, .29) | 1.66 (0.66–4.18, .28) |
| Antibiotics in confirmed bacterial meningitis or probable bacterial meningitis with neutrophilic pleocytosis and no confirmed CNS infection | |||
| Under 12 h | 30.4 (7/23) | … | … |
| Over 12 h | 40.0 (2/5) | 1.52 (0.20–11.72, .68) | 2.22 (0.17–29.98, .55) |
| Amphotericin B–based cryptococcal meningitis treatment | |||
| Under 12 h | 18.2 (2/11) | - | - |
| Over 12 h | 32.4 (24/74) | 2.16 (0.43–10.98, .34) | 1.41 (0.24–8.31, .71) |
| Antituberculous treatment in patients with possible, probable, or definite tuberculous meningitis | |||
| Under 24 h | 23.5 (4/17) | - | - |
| Over 24 h | 48.4 (15/31) | 3.05 (0.77–12.10, .10) | 6.89 (1.01–46.99, .05) |
Abbreviation: CNS, central nervous system.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
